

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/R4CE9B4F6E1CEN.html>

Date: August 2022

Pages: 68

Price: US\$ 3,500.00 (Single User License)

ID: R4CE9B4F6E1CEN

Abstracts

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded by the RARA gene. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. It promotes the survival and development of early meiotic prophase spermatocytes. It regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5 and mediates retinoic acid-induced granulopoiesis.

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 3 respectively. Report covers products from therapy areas Dermatology, Oncology, Immunology, Ophthalmology, Respiratory, Central Nervous System, Gastrointestinal, Genetic Disorders, Hematological Disorders,

Infectious Disease, Male Health and Metabolic Disorders which include indications Acne Vulgaris, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Bronchopulmonary Dysplasia, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B, Batten Disease, Germ Cell Tumors, Hand Dermatitis, Inflammatory Bowel Disease, Kaposi Sarcoma, Male Contraception, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Neutropenia, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinopathy Of Prematurity, Sarcomas, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

The latest report Retinoic Acid Receptor Alpha - Drugs In Development, 2022, outlays comprehensive information on the Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

The report reviews Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics and enlists all their major and minor projects

The report assesses Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development

Advent Therapeutics Inc

Avecho Biotechnology Ltd

Galephar Pharmaceutical Research Inc

Io Therapeutics Inc

Novartis AG

Orphagen Pharmaceuticals Inc

Orphanix GmbH

Ortho Dermatologics Inc

Polaryx Therapeutics Inc

Selphagy Therapeutics Inc

Sunny BioDiscovery Inc

TherapyX Inc

Toko Pharmaceutical Industries Co Ltd

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(gemfibrozil + tretinoin) - Drug Profile

Product Description
Mechanism Of Action
History of Events
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
History of Events
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
History of Events
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
History of Events
IRX-5183 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OR-812 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBD-073 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize RAR Alpha and RXR Alpha for Acute Promyelocytic
Leukemia - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize RAR Alpha for Opthamology - Drug Profile
Product Description
Mechanism Of Action
History of Events
tamibarotene - Drug Profile
Product Description
Mechanism Of Action

History of Events

tazarotene - Drug Profile

Product Description

Mechanism Of Action

History of Events

tretinoin - Drug Profile

Product Description

Mechanism Of Action

History of Events

tretinoin - Drug Profile

Product Description

Mechanism Of Action

History of Events

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

History of Events

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

History of Events

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones

Featured News & Press Releases

Aug 03, 2022: Syros receives positive opinion on orphan drug designation from the European Medicines Agency for tamibarotene for the treatment of MDS

Feb 02, 2022: Syros receives FDA Orphan Drug Designation for tamibarotene for the treatment of MDS

Oct 28, 2021: The first and only tazarotene lotion indicated for acne vulgaris in patients 10 years of age and older, ARAZLO now available for patients by prescription across Canada

Oct 19, 2021: Ortho Dermatologics to present new data on ARAZLO at the 2021 Fall Clinical Dermatology Conference

Sep 10, 2021: RaQualia announces milestone payment from Syros

Sep 09, 2021: Syros announces first patient dosed in SELECT-AML-1 trial of

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Dru...

Tamibarotene in combination with Venetoclax and Azacitidine in newly diagnosed unfit AML

Aug 04, 2021: Health Canada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris

Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting

Dec 05, 2020: Syros presents new data from Phase 2 clinical trial of SY-1425 and announces plans to initiate registration-enabling trial in MDS and randomized Phase 2 trial in AML

Nov 04, 2020: Syros to present new data from phase 2 clinical trial of SY-1425 in oral presentations at 62nd ASH annual meeting

Jul 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States

Jun 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States

Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)

Jan 12, 2020: Syros announces new update on SY-1425

Dec 19, 2019: FDA approves Ortho Dermatologics' ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Advent Therapeutics Inc, 2022

Pipeline by Avecho Biotechnology Ltd, 2022

Pipeline by Galephar Pharmaceutical Research Inc, 2022

Pipeline by Io Therapeutics Inc, 2022

Pipeline by Novartis AG, 2022

Pipeline by Orphagen Pharmaceuticals Inc, 2022

Pipeline by Orphanix GmbH, 2022

Pipeline by Ortho Dermatologics Inc, 2022

Pipeline by Polaryx Therapeutics Inc, 2022

Pipeline by Selphagy Therapeutics Inc, 2022

Pipeline by Sunny BioDiscovery Inc, 2022

Pipeline by TherapyX Inc, 2022

Pipeline by Toko Pharmaceutical Industries Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/R4CE9B4F6E1CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R4CE9B4F6E1CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970